Floatz logo

CABAZITAXEL

Metastatic Prostate Neuroendocrine Carcinoma

Andrew J. Armstrong, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

32 Active assets in the Metastatic Prostate Neuroendocrine Carcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Phanes Therapeutics
Phase 2BB
Tarlatamab
Inkeun Park
Phase 2B
Oxodotreotide
Novartis Pharmaceuticals
Phase 2B
Alisertib
Weill Medical College of Cornell University
Phase 2B
Sacituzumab Tirumotecan
Virginia Commonwealth University
Phase 2CCC

View all 35 →

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →